Cancer remains a significant global health concern, often shrouded in fear and misunderstanding. While many associate cancer with a diagnosis, its progression and the mechanisms of death, particularly from solid tumors, are less commonly understood. Metastasis, the spread of cancer cells from the primary tumor to distant organs, is the leading cause of mortality. This process is not instantaneous but involves cancer cells physically entering circulation, surviving a hostile journey, evading immune surveillance, and successfully colonizing new environments. Therefore, metastasis is fundamentally a survival and trafficking challenge, not merely a growth problem.

Dr. Louise Nicola, an intraoperative neurophysiologist, highlights the critical role of exercise in influencing the biological environment that cancer cells inhabit. She emphasizes that exercise is not simply a general healthy habit but a physiological signal that actively alters this environment. This perspective is crucial for understanding how exercise can impact cancer outcomes, moving beyond motivational rhetoric to evidence-based conclusions.

Understanding Cancer and Metastasis

Cancer, at its core, represents a breakdown of normal cellular regulation. Healthy cells adhere to instructions regarding growth, division, repair, and death, possessing self-destruct mechanisms and responding to their environment. Cancer arises when cells accumulate genetic and epigenetic changes, enabling them to disregard these controls, evade apoptosis, and proliferate uncontrollably.

However, initiation alone does not explain cancer's lethality. The danger escalates when cancer cells gain the ability to invade surrounding tissues and, more significantly, to spread to distant organs—a process known as metastasis. This spread occurs when parts of the primary tumor, termed circulating tumor cells (CTCs), enter the bloodstream or lymphatic system. These cells must then navigate a hostile journey, evade the immune system, and establish new tumors in organs like the liver, lungs, or brain. Metastasis is the primary driver of death from solid tumors, as the original tumor, if confined to a non-vital organ like the breast or prostate, may not be immediately life-threatening.

The stage of cancer often reflects its behavior: early-stage cancers are typically local, targeted for removal or destruction of the primary tumor. Advanced-stage cancers exhibit systemic behavior, with detectable metastasis or a high likelihood of microscopic spread. The critical insight is that metastasis is a complex process involving survival and trafficking, influenced by blood flow dynamics, the immune system, and the metabolic environment.

Exercise and Cancer Prevention

Large-scale prospective cohort studies provide substantial evidence linking physical activity to reduced cancer incidence. The NIH AARP Diet and Health Study, which followed over 150,000 adults, found that high levels of physical activity were associated with a lower incidence of several cancers, including colorectal and breast cancer. Importantly, these associations persisted even after adjusting for body mass index (BMI), suggesting that exercise offers benefits beyond weight loss. Similar findings have been observed in the Nurses' Health Study and the Health Professionals Follow-up Study, where physical activity correlated with reduced colon cancer and, in women, reduced breast cancer risk, again with adjustments for confounding factors like weight, smoking, alcohol, and diet.

The persistence of these associations after adjusting for BMI underscores that exercise's impact extends beyond weight management, influencing mechanisms such as insulin regulation, chronic inflammation, immune surveillance, and muscle metabolism. While not all cancers show the same relationship with exercise, consistent evidence points to benefits for colorectal, post-menopausal breast, and endometrial cancers, with emerging data for others.

Exercise During Cancer Treatment

For individuals diagnosed with cancer, exercise transitions from a long-term risk modifier to an intervention that can directly impact treatment tolerance and outcomes. Randomized controlled trials (RCTs) are the gold standard for this evidence. The landmark CARE trial, which investigated combined aerobic and resistance exercise in breast cancer patients undergoing chemotherapy, demonstrated that exercise improved physical function and reduced fatigue. Resistance training, in particular, helped preserve lean muscle mass, which is vital for metabolic reserve, drug metabolism, and overall tolerance to treatment-induced stress.

Other trials, such as the ERASE trial, have explored exercise interventions in various cancer populations, assessing not only fatigue and fitness but also psychological endpoints like fear of cancer progression. Cancer treatment is both a physiological and psychological stressor, and exercise can improve the patient's sense of control and well-being during this challenging period.

Crucially, exercise can influence treatment completion rates. When patients can better tolerate treatment, oncologists are less likely to need to reduce doses or delay therapy, which can be critical for long-term outcomes. Multiple trials indicate that exercise is associated with improved treatment tolerance, with some studies showing that patients in resistance training groups were more likely to complete their planned chemotherapy doses on schedule. This evidence has led guideline bodies, including the American Society of Clinical Oncology, to recommend that patients receiving curative intent treatment engage in both aerobic and resistance exercise.

Furthermore, exercise may directly influence tumor response. Tumors often develop abnormal blood vessels, which can impair the delivery of chemotherapy drugs and reduce the effectiveness of radiation therapy due to low oxygen levels (hypoxia). Pre-clinical studies suggest that exercise can normalize tumor vasculature, improving blood flow, oxygenation, and drug delivery. Clinical studies in rectal cancer patients undergoing neoadjuvant chemoradiation have shown that those who exercised were more likely to achieve a pathologic complete response, meaning no detectable tumor remained after treatment.

It is important to note that exercise during treatment requires careful consideration of individual tolerance, treatment toxicity, and specific cancer types. Exercise oncology emphasizes appropriate dosing, supervision when necessary, and personalized plans rather than generic fitness advice.

Exercise in Cancer Survivorship and Recurrence

Following primary treatment, exercise plays a significant role in survivorship. It aids in recovery from the physiological damage of treatment, helping to rebuild muscle, improve cardiovascular capacity, enhance sleep, and reduce anxiety and depression. Multiple RCTs and meta-analyses in exercise oncology confirm these benefits.

The question of whether exercise reduces recurrence and cancer-specific mortality is also being investigated. Observational studies in colon cancer survivors have linked higher levels of physical activity after treatment to improved disease-free survival and overall survival. Similarly, large observational studies in breast cancer survivorship consistently show an association between higher physical activity levels post-diagnosis and reduced breast cancer-specific mortality. However, confounding factors, such as healthier individuals being more likely to exercise, necessitate caution in interpreting these findings as direct causation.

Mechanistically, exercise may influence recurrence by impacting the survival and trafficking of dormant or microscopic metastatic cells. Studies exposing human cancer cells to flow conditions mimicking increased blood flow have shown that higher sheer stress decreases the survival of circulating tumor cells. This suggests that repeated bouts of increased blood flow during exercise could make the circulatory environment less hospitable to metastatic cells.

Exercise also enhances immune surveillance by mobilizing natural killer cells and cytotoxic T cells, and in pre-clinical models, it increases immune cell infiltration into tumors. Metabolic signaling is another key area, with exercise improving insulin sensitivity, lowering insulin and IGF-1 signaling, and reducing chronic inflammation, all of which can influence the growth signals available to residual cancer cells. Additionally, maintaining muscle mass is crucial, as low muscle mass in survivors is associated with a higher risk of physical decline and worse long-term outcomes.

Limitations and Implementation

While the evidence for exercise's benefits across the cancer continuum is compelling, it is essential to acknowledge limitations. Not all cancers respond similarly to exercise prevention, and not all patients can tolerate the same intensity during treatment. Certain side effects, such as severe gastrointestinal toxicity, neuropathy, or bone metastases, may require modifications or contraindicate high-intensity exercise. The evidence for exercise reducing recurrence is still evolving, with much of it derived from observational studies.

For practical implementation, a decision framework is recommended:

• Prevention: Meeting public health guidelines for moderate-to-vigorous physical activity, supplemented with resistance training, is supported by strong evidence, as both aerobic capacity and muscle mass are biologically protective.
• During Treatment: The goal is preservation—maintaining muscle, function, sleep, and mood, while supporting treatment completion. This typically involves a combination of aerobic and resistance exercise, scaled to individual tolerance and ideally guided by medical professionals.
• Survivorship: The focus shifts to rebuilding physiological reserve eroded by treatment and continuing the beneficial metabolic and immune signaling patterns established through exercise, aiming to regain muscle mass, strength, and aerobic capacity.

Ultimately, exercise is not a motivational concept but a repeated physiological stress that remodels metabolism, immunity, circulation, and muscle—systems intricately involved in cancer at every stage.